{"count": 1, "results": [{"_id": "40454360", "pmid": 40454360, "title": "Efficacy of the Optimal Dosage of Lisinopril in Inhibiting Myofibroblast Differentiation for Attenuating Rheumatic Heart Disease Progression: An in Vitro Study.", "journal": "J Tehran Heart Cent", "authors": ["Lefi A", "Asmarani DN", "Dharmadjati BB", "Suwanto D", "Saputra ME", "Pravitasari VL", "Anandita FA"], "date": "2024-10-01T00:00:00Z", "doi": "10.18502/jthc.v19i4.17610", "meta_date_publication": "2024 Oct", "meta_volume": "19", "meta_issue": "4", "meta_pages": "256-263", "score": 50277.074, "text_hl": "Efficacy of the Optimal Dosage of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ in Inhibiting Myofibroblast Differentiation for Attenuating @<m>DISEASE_Rheumatic_Heart_Disease</m> @DISEASE_MESH:D012214 @@@Rheumatic Heart Disease@@@ Progression: An in Vitro Study.", "citations": {"NLM": "Lefi A, Asmarani DN, Dharmadjati BB, Suwanto D, Saputra ME, Pravitasari VL, Anandita FA. Efficacy of the Optimal Dosage of Lisinopril in Inhibiting Myofibroblast Differentiation for Attenuating Rheumatic Heart Disease Progression: An in Vitro Study. J Tehran Heart Cent. 2024 Oct;19(4):256-263. PMID: 40454360", "BibTeX": "@article{40454360, title={Efficacy of the Optimal Dosage of Lisinopril in Inhibiting Myofibroblast Differentiation for Attenuating Rheumatic Heart Disease Progression: An in Vitro Study.}, author={Lefi A and Asmarani DN and Dharmadjati BB and Suwanto D and Saputra ME and Pravitasari VL and Anandita FA}, journal={J Tehran Heart Cent}, volume={19}, number={4}, pages={256-263}}"}}]}